Pegvaliase
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Phenylketonuria (PKU)
Conditions
Phenylketonuria (PKU)
Trial Timeline
Jun 6, 2022 → Nov 1, 2033
NCT ID
NCT05813678About Pegvaliase
Pegvaliase is a pre-clinical stage product being developed by BioMarin Pharmaceutical for Phenylketonuria (PKU). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05813678. Target conditions include Phenylketonuria (PKU).
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06305234 | Pre-clinical | Recruiting |
| NCT05579548 | Pre-clinical | Recruiting |
| NCT05270837 | Phase 3 | Active |
| NCT05813678 | Pre-clinical | Recruiting |
| NCT03792451 | Pre-clinical | Completed |
| NCT03694353 | Phase 3 | Completed |
Competing Products
20 competing products in Phenylketonuria (PKU)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SYNB1934v1 + Placebo | Synlogic | Phase 3 | 69 |
| SYNB1618 + Placebo | Synlogic | Phase 1/2 | 33 |
| SYNB1618 + SYNB1934 | Synlogic | Phase 2 | 44 |
| Kuvan® | Merck | Phase 3 | 77 |
| Kuvan® | Merck | Approved | 85 |
| SAR444836 | Sanofi | Phase 1/2 | 40 |
| Kuvan | BioMarin Pharmaceutical | Pre-clinical | 20 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 49 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 49 |
| Sapropterin (Kuvan) | BioMarin Pharmaceutical | Pre-clinical | 20 |
| BMN 165 (rAvPAL-PEG) | BioMarin Pharmaceutical | Phase 2 | 49 |
| BMN 307 | BioMarin Pharmaceutical | Phase 1/2 | 38 |
| Sapropterin | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Sapropterin dihydrochloride + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |
| BMN165 20mg/day + BMN165 40mg/day + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 3 | 74 |
| saproterin dihydrochloride | BioMarin Pharmaceutical | Approved | 82 |
| sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placebo | BioMarin Pharmaceutical | Phase 1 | 30 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 2 | 49 |